ImmunityBio reports Phase 3 ANKTIVA-plus-BCG bladder cancer data
ImmunityBio reports 84% cystectomy avoidance at three years and complete responses beyond 53 months in patients with BCG-unresponsive NMIBC, with or without papillary tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG — Unresponsive NMIBC With CIS, With or Without Papillary Tumors
For best results when printing this announcement, please click on link below: ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA(® )Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors Peer-reviewed publication r
ImmunityBio Reports Long-Term ANKTIVA Data in Bladder Cancer Study
ImmunityBio said long-term data from its Phase 2/3 QUILT-3.032 study (N=100) were published in the Journal of Urology. The study reported 84% cystectomy avoidance at three years and complete responses beyond 53 months among patients receiving ANKTIVA plus BCG for BCG-unresponsive NMIBC with CIS, with or without papilla